Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiovascular Risk Assessment After Sofosbuvir And Daclatasvir Regimen For Chronic Hepatitis C Virus Infection.

JPMA. The Journal of the Pakistan Medical Association - 1 Apr 2023

Maher Kareem Ali, Biomy Reda, Youssef Mahmoud Mohammed, Zaghloul Mariam Salah, Haseeb Wael Anwar

Abstract excerpt

Objectives: To assess cardiovascular risk after sofosbuvir and daclatasvir antiviral combination therapy in chronic hepatitis C virus patients. Method: The prospective cohortstudy was conducted at the Kafrelsheikh University Hospital, Egypt, from December 2019 to December 2021, and comprised adult patients of either gender with chronic hepatitis C virus and with minimum ejection fraction 40%. They were classified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Heart Disease Risk Factors

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Pyrrolidines

Share to Sofosbuvir

Source

Identifiers

PMID: 37482846
DOI: 10.47391/JPMA.EGY-S4-28

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Cardiovascular Risk Assessment After Sofosbuvir And Daclatasvir Regimen For Chronic Hepatitis C Virus Infection.PMID 37482846Read ↗

Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.Semantic proximity Read ↗

Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study.Semantic proximity Read ↗

Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Assessment of ten-year cardiovascular disease risk in Bangladesh: A comparative analysis of laboratory and non-laboratory-based WHO risk prediction modelsSemantic proximity Read ↗

[The risk groups of infection with hepatitis С virus in conditionally healthy population of the Belgorod oblast].Semantic proximity Read ↗

Heart Rate Variability in Patients with Cirrhosis: A Systematic Review and Meta-analysisSemantic proximity Read ↗

The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.Semantic proximity Read ↗

Chronic Hepatitis C and comorbidities: real-world study to evaluate impact in outcomes after treatment with sofosbuvir-based regimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.